Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gotcha so this still had potential? They are just trying to get some capital out of the last months run ? INFI did the same thing after I purchased.
They’ll announce the price pre-market tomorrow. Market will over react, that’s when you buy.
Bad. Small cap pharma companies always do this right after some good news.
Is this good or bad ? I mean issuing more shares because there aren’t a ton ?
* * $INFI Video Chart 02-11-2021 * *
Link to Video - click here to watch the technical chart video
Looks like offering coming from the way it’s trading
Wow this comment didn’t age too well, haha...
This post didn’t age well, did it? Heheh
INFI~~2.01 Infinity Pharmaceuticals : Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer
01/06/2021 | 09:12am EST
share with twitter
share with LinkedIn
share with facebook
-Infinity Planning New, Registration-Enabling Study in Advanced Urothelial Cancer Leveraging Encouraging Data from MARIO-275-
-MARIO-275 Data to be Presented at a Major Medical Meeting in Q1 2021-
-Infinity Provides 2021 Milestones and Financial Guidance-
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company’s randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy which is approved in this setting.
“The MARIO-275 study provided Infinity with important insights to shape the future of eganelisib in urothelial cancer,” said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. “The data from the 49 patients enrolled in the study are very encouraging. The combination was well tolerated at the 30 mg dose of eganelisib and provided patient benefit relative to the placebo controlled arm on important response rate and progression free survival measures, particularly in urothelial cancer patients with low levels of PD-L1 expression who respond poorly to checkpoint inhibitors alone. We are leveraging the clinical and translational learnings from MARIO-275 in planning a new, registration-enabling study of eganelisib in patients with advanced urothelial cancer. We look forward to presenting our data from MARIO-275, which support our clinical strategy, at a major medical meeting in Q1 2021, with details for our new, planned trial to follow in the coming months after discussions with regulatory authorities.”
Encouraging data including in post-CPI progression and PD-L1 low patients was presented at The Society for Immunotherapy of Cancer (SITC) in November and the San Antonio Breast Cancer Symposium (SABCS) in Q4 2020.
Program Updates and Guidance:
MARIO-275
The MARIO-275 Independent Data Monitoring Committee (IDMC) determined that there was a favorable risk/benefit for patients after the successful implementation of a dose reduction from 40mg QD to 30mg QD to reduce the reversible liver enzyme elevations that were reported after the first scheduled MARIO-275 IDMC meeting.
Infinity has completed the evaluation of the 49 patients enrolled in the study with encouraging safety, response rate and progression free survival (PFS) data, including in patients with low levels of PD-L1 expression.
Infinity will be presenting the MARIO-275 data at a major medical meeting in Q1 2021.
As a result of the encouraging data, the Company is planning a new registration-enabling study and will not re-open enrollment in MARIO-275.
MARIO-3
Data was presented at SABCS in December which showed the benefit of adding eganelisib to standard of care Tecentriq® and Abraxane® therapy for front-line TNBC patients.
Progression-free survival and updated overall response rate data for TNBC will be presented in 1H and 2H of 2021.
Renal cell carcinoma data to be presented in 1H 2022.
2021 Financial Guidance
Infinity ended 2020 with approximately $34.1 million in cash and investments (unaudited) and plans to report its fourth quarter and full-year 2020 financial results in March. The Company expects to have cash through 2021 based on its current operating plans, which excludes additional financing or business activities, and excludes a potential $5 million milestone payment from BVF for positive Phase 3 patidegib data and any milestones from, or the sale of the Company’s equity interest in, PellePharm.
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding: the therapeutic potential of eganelisib; plans to present data; plans to not re-open MARIO-275 for enrollment; plans for a registration-enabling study in urothelial cancer; financial guidance; and the Company's ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. For example, there can be no guarantee that eganelisib will successfully complete necessary preclinical and clinical development phases. Further, there can be no guarantee that any positive developments in Infinity's product portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the cost, timing and results of clinical trials and other development activities that may be delayed or disrupted by the COVID-19 pandemic or otherwise; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; Infinity's ability to obtain and maintain requisite regulatory approvals; unplanned cash requirements and expenditures; development of agents by Infinity's competitors for diseases in which Infinity is currently developing or intends to develop eganelisib; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for eganelisib. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's annual report and quarterly reports filed with the Securities and Exchange Commission (SEC), and in other filings that Infinity makes with the SEC, available through the Company’s website at www.infi.com. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity does not undertake and expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005497/en/
Wonderful still more to come.
? My a$$ made bank from $1.62.. how did you do?
The patent just got granted today how could it be old. What people will do for a few $$ is unreal. Do some DD and you will see that
Still liking that setup lol, short from $1.62 was a no brainer with this old patent
This one falls from here
chart looks good
Sorry, this will not hold the gains
But you're saying news?
The news isn’t all that is what I’m saying
Average daily volume under 200,000, volume almost 7,000,000 today
Somebody knows something and buying shares before the a.m.
Looks like it could be a decent gapper pm. She wants to go. Clay crew need to hop on the next one. We are out of rubber mallets and ball bearings here.
perfect setup to make money, glad I loaded today
Please show a screen shot of ur short lmao..im gong with all talk with u!!
Perfect short setup
News not all that
agreed! after hours $1.54
Tomorrow should be interesting
* * $INFI Video Chart 10-15-2019 * *
Link to Video - click here to watch the technical chart video
Don't bet against Harvard
Management is a dream team
Truly an underrated stock
News: $INFI Infinity Pharmaceuticals To Present At The 2019 BIO International Convention
CAMBRIDGE, Mass. , May 29, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that members of the management team will be participating in the 2019 BIO International Convention at Pennsylvania Convention Center, Philadelphia, PA. Adelene Perkins , ...
Got this from https://marketwirenews.com/news-releases/infinity-pharmaceuticals-to-present-at-the-2019-bio-international-convention-8262820.html
please expand on your thoughts
Management is a dream team
Right in the heart of Harvard
Nice share structure
Been watching this closely
News: $INFI Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update
CAMBRIDGE, Mass. , March 14, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full year 2018 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate t...
Find out more https://marketwirenews.com/news-releases/infinity-pharmaceuticals-reports-full-year-2018-financial-results-and-provides-company-update-7846734.html
News: $INFI Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer
CAMBRIDGE, Mass. , March 14, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has entered into a master clinical supply agreement under which Roche will supply atezolizumab (Tecentriq ® ) to Infinity for use in MARIO-3, a Phase ...
Read the whole news https://marketwirenews.com/news-releases/infinity-to-initiate-mario-3-a-phase-2-multi-arm-study-evaluating-ipi-549-in-front-line-triple-negative-breast-cancer-and-renal-cell-cancer-7846680.html
News: $INFI Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA(TM) for $30 Million Gross Proceeds
CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today a royalty monetization with HealthCare Royalty Partners (HCR) for the right to receive certain royalty payments based on worldwide annual net sales of COPIKTRA™...
In case you are interested https://marketwirenews.com/news-releases/infinity-pharmaceuticals-announces-royalty-monetization-of-copiktra-tm-for-30-million-gross-proceeds-7811048.html
Picking up even more INFI after the holidays.
Come on INFI, drop drop!
If this goes below a dollar I will be the most happy buyer of all time lol.
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
504
|
Created
|
11/17/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |